Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NC-6300
- Development stage
- Phase 2
- Lead developer
- Nano Holdings
- Modality
- Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
NC-6300 is a novel epirubicin drug-conjugated polymeric micelle developed using cutting-edge micellar nanoparticle technology. It comprises epirubicin covalently bound to PEG polyaspartate block copolymer through an acid-labile hydrazone bond, forming a micellar structure of 40-80 nm in diameter in an aqueous environment. The nanoparticle has a pH-sensitive linker which enables selective epirubicin release into tumor tissue, exhibiting increased tumor accumulation compared to small-molecule epirubicin through enhanced pharmacokinetics. This formulation aims to extend the antitumor effect while reducing the cardiotoxicity associated with conventional epirubicin.
- Other names
- Nanoparticle Epirubicin
02
Targets
TOP2A (DNA topoisomerase II)DNA
Beyond the preview
Go deeper on NC-6300.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NC-6300.